 Yes, thank you for this question. One of the major achievements of this project is to show the possibility of a close collaboration among Amilidosi Center, International Amilidosi Center. This led an extraordinary results of more than 2,000 patients enrolled in this important study and probably in the upcoming months we will see more patients enrolled. And as reported by Dr. Castritis yesterday, there is unfortunately still the need for abectic knowledge about the disease. Unfortunately, most of the patients also in the last course of the study are diagnosed late when the organ damage is really advanced. Also in our perspective in the prospective study run by the Italian Medicine Agency in patients treated with Bortezomib there is also in this case patients in the really advanced stage of the disease diagnosis. So, this is one of the main results of those studies. So, before 2010 oral methanol index metazone was the standard of care for patients with AL amilidosis. The best achievement of adding Bortezomib to alkylators was the improvement of the rate and the quality of hematologic response. Importantly, few weeks ago, few months ago was published on the Journal of Clinical Oncology the final results of the first phase three study in patients with the AL amilidosis. In these studies we compare the use of the standard of care Melfland index metazone versus Bortezomib Melfland index metazone. And in this study the addiction of Bortezomib to the standard of care resulted in an improvement in terms of hematologic response that reached almost 80 percent and importantly this regimen was associated with a significant improvement in overall survival. So, the addiction of alkylating agents such as signecyborgdicyclerophosphamine should be considered as an important game changer in this disease. So, we have to say that Bortezomib combinations are the main stage of treatment for newly diagnosed AL amilidosis patients. And again, as I said before, after the results of the phase three study on JCO, we might consider Bortezomib Melfland index metazone as the new standard of care. This should be a combination very effective and relatively inexpensive. Unfortunately, Melfland the use of oral Melfland is associated with limitations due to in particular for those patients with the kidney failure and for those with non-permanent contraindication to autologous sense and transplant. So, Bortezomib Melfland index metazone should be considered the standard of care for patients non-candidate for autologous sense and transplant and signecyborgdicyclerophosphamine should be considered the best option in all the other patients. And yes, this drug, this combination is now one of the most used across Europe. Early diagnosis is still an adamant need for AL amilidosis patients. This is a big problem and I think that the important step forward is the awareness about the disease. And I'm really happy because the educational program of the arch meeting this year decided to have a talk about the management of AL amilidosis and also about other monoclonal gamopathy of clinical significance. This is a really important point because the awareness of hematologist is fundamental in order to reduce the time from the first suspicion to the final diagnosis. The second step is to increase the awareness of cardiologist and the nephrologist because those specialists are usually the first physicians that have to make the suspicion in patients with amilidosis. One of the way to reduce the time from the clinical suspicion to have a nearly diagnosis is to increase awareness and secondly to screen for those patients with high risk of amilidosis as we do in our center. In our hematology department we collected biomarkers for cardiac damages such as anti-probium P in all patients with monoclonal gamopathy of undetermined significance and an abnormal free life chain couple under ratio. In this way we identified patients with a really early diagnosis with no organ damage within a pre-syntomatic stages. The median time to get the final diagnosis is still too high and also the mayor researcher reported this in an application a few years ago showing that more than 10 months from the identification of the monoclonal gamopathy could be a median time from diagnosis so still too long. One of the major achievement of this project again is to see the close collaboration among experts in the field of amilidosis. We know that it is a rare disease but we collaborate a lot in the field of amilidosis and this is really important in order to to find important point for our patients and I would like to take this opportunity to thank all the researchers that took the time to fill the survey also in this difficult time of the covid pandemic. I think that one of the major results of this first analysis was to show that the severity and the mortality rate of the SARS-CoV-2 infection is in the range of the general population but we have to wait the final results and the analysis and also I have to say that unfortunately in the last few weeks we have a huge increase in the numbers of patients that were diagnosed due to the second European wave of covid-19. So thank you for collaborating this project and we will see the final results soon hopefully.